Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ISLB 2021 | ctDNA MRD as a biomarker for solid tumors

Name: ctDNA MRD as a biomarker for solid tumors
Uploaded: 2021-10-20T00:00:00Z
Duration: 1 min 9 s

Aadel Chaudhuri • 20 Oct 2021

ISLB 2021

Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

IMvigor010

Aadel Chaudhuri, MD, PhD, Washington University School of Medicine, St. Louis, USA, discusses what research still needs to be done into using ctDNA as a biomarker for minimal residual disease (MRD) post-surgery for patients with solid tumors. Dr Chaudhuri also compares prognostic and predictive biomarkers. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.